Table 2.
Outcomes within 30 days after TAVI stratified by patients’ risk profile according to HFR score
| Endpoint | All patients, n = 21,430 | Low risk (HFR score < 5), n = 10,973 | Intermediate risk (HFR score 5–15), n = 7,946 | High risk (HFR score > 15), n = 2,547 | p value |
|---|---|---|---|---|---|
| Mortality, n (%) | 665 (3.1) | 175 (1.6) | 346 (4.4) | 144 (5.7) | < 0.001 |
| Myocardial infarction, n (%) | 82 (0.4) | 36 (0.3) | 33 (0.4) | 13 (0.5) | 0.111 |
| Stroke or TIA, n (%) | 625 (2.9) | 137 (1.3) | 255 (3.2) | 233 (9.1) | < 0.001 |
| Bleeding1, n (%) | 2.696 (12.6) | 803 (7.3) | 1.260 (15.9) | 633 (24.9) | < 0.001 |
| Access-related vascular complication1, n (%) | 457 (2.1) | 201 (1.8) | 182 (2.3) | 74 (2.9) | < 0.001 |
| Permanent device implantation, n (%) | 3,008 (14.0) | 1,386 (12.7) | 1,184 (14.9) | 438 (17.2) | < 0.001 |
| Acute renal failure with need for dialysis, n (%) | 375 (1.7) | 63 (0.6) | 178 (2.2) | 134 (5.3) | < 0.001 |
Significant values are in bold
Censoring taken into account
HFR hospital frailty risk, TAVI Transcatheter Aortic Valve Implantation
1Within 7 days